Godwin Mary E. 4
4 · Nautilus Biotechnology, Inc. · Filed Sep 18, 2024
Insider Transaction Report
Form 4
Godwin Mary E.
Senior VP, Operations
Transactions
- Sale
Common Stock
2024-09-17$2.85/sh−35,000$99,869→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-17−35,000→ 400,368 totalExercise: $0.46Exp: 2030-01-30→ Common Stock (35,000 underlying) - Exercise/Conversion
Common Stock
2024-09-17$0.46/sh+35,000$16,100→ 35,000 total
Footnotes (2)
- [F1]Represents the weighted average share price of an aggregate total of 35,000 shares purchased in the price range of $2.80 to $2.99 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 21, 2020.